Company: TDBCP
Filing Date: 2025-07-09
Form Type: 424B2
Source: 0001140361-25-025346
Chunk: 23

Company: TORONTO DOMINION BANK
Filing Date: 2025-07-09
Form: 424B2
Chunk 23
---
 it obtained from any other source or the information provided below. Each Reference Asset is registered under the Securities Act of 1933, the Investment Company Act of 1940, each as amended, and/or the Exchange Act. Companies with securities registered with the SEC are required to file financial and other information specified by the SEC periodically. Information filed by each Investment Adviser with the SEC can be reviewed electronically through a website maintained by the SEC. The address of the SEC’s website is http://www.sec.gov. Information filed with the SEC by each Reference Asset can be located by reference to its SEC file number provided below. The graphs below set forth the information relating to the historical performance of each Reference Asset. The graphs below show the daily historical Closing Values of each Reference Asset for the periods specified. We obtained the information regarding the historical performance of each Reference Asset in the graphs below from Bloomberg Professional ®service (“Bloomberg”). The Closing Values may be adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs, delistings and bankruptcy. We have not independently verified the accuracy or completeness of the information obtained from Bloomberg. The historical performance of each Reference Asset should not be taken as an indication of its future performance, and no assurance can be given as to the Final Value of any Reference Asset. We cannot give you any assurance that the performance of the Reference Assets will result in a positive return on your initial investment.

| TD SECURITIES (USA) LLC | P-17 |

| SPDR®S&P®Biotech ETF |

We have derived all information contained herein regarding the SPDR ®S&P ®Biotech ETF (the “XBI Fund”) and the target index, as defined below, from publicly available information. Such information reflects the policies of, and is subject to changes by, the XBI Fund’s investment adviser, SSGA Funds Management, Inc. (“SSGA” or the “investment adviser”) and the index sponsor of the target index, as defined below. The XBI Fund is one of the separate investment portfolios that constitute the SPDR ®Series Trust (“SPDR”). The XBI Fund seeks to provide investment results that correspond generally to the total return performance, before fees and expenses, of the S&P ®Biotechnology Select Industry™ Index (the “target index”). The target index seeks to measure the performance of the biotechnology segment of the U.S. equity market and includes companies that have been identified as biotechnology companies on the basis of general industry classification from a